April 22nd 2024
In separate, live virtual events, Kami J. Maddocks, MD, and Sairah Ahmed, MD, discussed the use of loncastuximab tesirine for a patient with later-line diffuse large B-cell lymphoma.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Real-World Data Support Use of Polatuzumab Vedotin for Heavily Pretreated Patients with R/R DLBCL
October 16th 2020Patients with relapsed or refractory diffuse large B-cell lymphoma who have not found success in 2 or more lines of therapy face stiff odds, but new data suggest polatuzumab vedotin–based therapies may help improve outcomes.
Read More
AUTO3 CAR T Cell Appears Promising as Treatment of Relapsed/Refractory DLBCL
October 14th 2020The first CD19/22-directed dual targeting CAR T cell AUTO3 demonstrated a tolerable and best-in-class safety profile as treatment of patients with relapsed/refractory diffuse large B-cell lymphoma.
Read More